Cadrenal Fast Tracked for Thromboembolism in End-Stage Renal Disease, Atrial Fibrillation

  Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease (ESRD) and atrial fibrillation (AFib).

https://finance.yahoo.com/news/cadrenal-therapeutics-nasdaq-cvkd-granted-133000290.html